Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
Latest Information Update: 24 Jul 2007
At a glance
- Drugs Lenalidomide (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 29 Oct 2005 New trial record.